BioTuesdays

Category - Markets

Bovie Medical

Piper starts Bovie Medical at overweight

Piper Jaffray initiated coverage of Bovie Medical (NYSE:BVX) with an “overweight” rating and $6 price target. The stock closed at $4.24 on Friday. Bovie is best known within the operating room for its electrocautery...

Profound Medical Logo

Mackie ups Profound Medical price target to $4.40

Mackie Research Capital raised its price target for Profound Medical (TSX-V:PRN) to $4.40 from $3.30 after the company reported third quarter results. The stock closed at $1 on Thursday. Analyst Andre Uddin writes that...

Repros Therapeutics

Ladenburg upgrades Repros Therapeutics to buy

Ladenburg Thalmann upgraded Repros Therapeutics (NASDAQ:RPRX) to “buy” from “neutral,” with a new price target of $5.50. The stock closed at $1.93 on Wednesday. In a new report, analyst Matthew Kaplan writes that Repros...

iRhythm Technologies

Canaccord and BTIG start iRhythm at buy

Canaccord Genuity and BTIG initiated coverage of iRhythm Technologies (NASDAQ:IRTC) with “buy” ratings and price targets of $31 and $28, respectively. The stock closed at $24.23 on Friday. iRhythm is a digital health...

T2 Biosystems Logo

Leerink resumes coverage of T2 at market perform

Leerink resumed coverage of T2 Biosystems (NASDAQ:TTOO) with a “market perform” rating and $5 price target. The stock finished at $6.31 on Wednesday. “While we view T2’s proprietary T2MR pathogen detection technology...

Invitae

Leerink resumes coverage of Invitae at OP

Leerink resumed coverage of Invitae (NASDAQ:NVTA) with an “outperform” rating and $12 price target. The stock closed at $8.44 on Wednesday. Analyst Puneet Souda writes that Invitae is a high growth, commercial-stage...

Applied Genetic

Roth upgrades Applied Genetic to buy

Roth Capital Partners upgraded Applied Genetic Technologies (NASDAQ:AGTC) to “buy” from “neutral” and raised its price target to $15 from $12. The stock jumped $2.15 to $9.20 in afternoon trading on Wednesday. “With...

Keryx Biopharmaceuticals Logo

Maxim upgrades Keryx to buy

Maxim Group upgraded Keryx Biopharmaceuticals (NASDAQ:KERX) to “buy” from “hold” and reinstated its $7 price target after the FDA approved its application for a second contract manufacturer of Auryxia for the control of...

CorWave

CorWave in $17.1-million Series B Financing

Closely-held CorWave has completed a $17.1-million Series B financing with existing shareholders, including Sofinnova Partners, Bpifrance and Seventure, and two new investors: Novo Seeds, which led the round, and Ysios...

Tandem Diabetes Care

Stifel downgrades Tandem Diabetes to hold

Stifel downgraded Tandem Diabetes (NASDAQ:TNDM) to “hold” from “buy” and slashed its price target to $3.50 from $15 after a more disappointing than expected third quarter earnings performance and now sharply lower...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.